Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSFC immunomonitoring of minimal residual autoimmunity in rituximab-treated ANCA-associated vasculitis
NL-OMON43121Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of rituximab in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by Leiden University Medical Center. Primary endpoint: Composition of memory B-cell and plasma cell compartment. Started Apr 2017; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NL-OMON43121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43121.